Baker Bros. Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Baker Bros. Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$71.5M	Hold	4,345,736	–	–	0.41%	32
2025 Q4	$68.1M	Sell	4,345,736 -570,359	-12%	-$7.69M	0.4%	32
2025 Q3	$36.4M	Hold	4,916,095	–	–	0.26%	37
2025 Q2	$22.2M	Hold	4,916,095	–	–	0.22%	35
2025 Q1	$22.8M	Hold	4,916,095	–	–	0.25%	32
2024 Q4	$34.1M	Hold	4,916,095	–	–	0.36%	32
2024 Q3	$26.1M	Hold	4,916,095	–	–	0.27%	37
2024 Q2	$18.4M	Hold	4,916,095	–	–	0.24%	40
2024 Q1	$34.7M	Hold	4,916,095	–	–	0.43%	33
2023 Q4	$27.8M	Hold	4,916,095	–	–	0.32%	35
2023 Q3	$23.5M	Buy	4,916,095 +1,892,144	+63%	+$12.2M	0.14%	35
2023 Q2	$20.7M	Buy	3,023,951 +2,648,856	+706%	+$17.1M	0.12%	42
2023 Q1	$2.92M	Buy	+375,095	New	+$2.61M	0.02%	83

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Baker Bros. Advisors's GLUE Position: Q1 2026 in Review

Baker Bros. Advisors held its Monte Rosa Therapeutics (GLUE) position steady in Q1 2026 at 4,345,736 shares worth $71.5M. The position accounts for 0.41% of the portfolio, ranked #32.

Baker Bros. Advisors first reported a position in GLUE in Q1 2023 and has held it in 13 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

Baker Bros. Advisors held 4,345,736 shares of Monte Rosa Therapeutics worth $71.5M as of Q1 2026.
Baker Bros. Advisors left its Monte Rosa Therapeutics share count unchanged in Q1 2026.
Monte Rosa Therapeutics made up 0.41% of Baker Bros. Advisors's portfolio in Q1 2026, its #32 holding.
Baker Bros. Advisors first reported a position in Monte Rosa Therapeutics in Q1 2023 and has held it in 13 quarters since.
190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.